PL2736920T3 - Związek hamujący przekazywanie sygnałów przez szlak Notch - Google Patents

Związek hamujący przekazywanie sygnałów przez szlak Notch

Info

Publication number
PL2736920T3
PL2736920T3 PL12741192T PL12741192T PL2736920T3 PL 2736920 T3 PL2736920 T3 PL 2736920T3 PL 12741192 T PL12741192 T PL 12741192T PL 12741192 T PL12741192 T PL 12741192T PL 2736920 T3 PL2736920 T3 PL 2736920T3
Authority
PL
Poland
Prior art keywords
inhibitor compound
signaling inhibitor
notch pathway
pathway signaling
notch
Prior art date
Application number
PL12741192T
Other languages
English (en)
Polish (pl)
Inventor
Philip Arthur Hipskind
Gregory Alan Stephenson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL2736920T3 publication Critical patent/PL2736920T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL12741192T 2011-07-27 2012-07-18 Związek hamujący przekazywanie sygnałów przez szlak Notch PL2736920T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161512016P 2011-07-27 2011-07-27
US201161560486P 2011-11-16 2011-11-16
EP12741192.4A EP2736920B1 (en) 2011-07-27 2012-07-18 Notch pathway signaling inhibitor compound
PCT/US2012/047100 WO2013016081A1 (en) 2011-07-27 2012-07-18 Notch pathway signaling inhibitor compound

Publications (1)

Publication Number Publication Date
PL2736920T3 true PL2736920T3 (pl) 2015-11-30

Family

ID=46598983

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12741192T PL2736920T3 (pl) 2011-07-27 2012-07-18 Związek hamujący przekazywanie sygnałów przez szlak Notch

Country Status (36)

Country Link
US (1) US8569286B2 (enExample)
EP (1) EP2736920B1 (enExample)
JP (1) JP6027110B2 (enExample)
KR (1) KR101578309B1 (enExample)
CN (1) CN103732612B (enExample)
AP (1) AP4080A (enExample)
AR (1) AR087107A1 (enExample)
AU (1) AU2012287251B2 (enExample)
BR (1) BR112014001600B1 (enExample)
CA (1) CA2841178C (enExample)
CL (1) CL2014000175A1 (enExample)
CO (1) CO6862159A2 (enExample)
CR (1) CR20140036A (enExample)
CY (1) CY1116645T1 (enExample)
DK (1) DK2736920T3 (enExample)
DO (1) DOP2014000011A (enExample)
EA (1) EA023044B1 (enExample)
EC (1) ECSP14013179A (enExample)
ES (1) ES2544937T3 (enExample)
GT (1) GT201400012A (enExample)
HR (1) HRP20150771T1 (enExample)
HU (1) HUE027534T2 (enExample)
IL (1) IL229988A (enExample)
JO (1) JO3148B1 (enExample)
MA (1) MA35611B1 (enExample)
ME (1) ME02171B (enExample)
MX (1) MX356536B (enExample)
MY (1) MY184303A (enExample)
PE (1) PE20141061A1 (enExample)
PH (1) PH12014500215B1 (enExample)
PL (1) PL2736920T3 (enExample)
PT (1) PT2736920E (enExample)
RS (1) RS54135B1 (enExample)
SI (1) SI2736920T1 (enExample)
TW (1) TWI568730B (enExample)
WO (1) WO2013016081A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110506A2 (en) * 2013-01-14 2014-07-17 The Trustees Of Columbia University In The City Of New York Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk抑制劑
TWI609687B (zh) * 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
JO3491B1 (ar) * 2015-07-07 2020-07-05 Audion Therapeutics مركبات مثبطة لإشارات مسار notch
US9815850B2 (en) 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
US11564929B2 (en) 2016-04-12 2023-01-31 Eli Lilly And Company Combination therapy with Notch and PI3K/mTOR inhibitors for use in treating cancer
MX380779B (es) * 2016-04-12 2025-03-12 Lilly Co Eli Terapia combinatoria con inhibidores notch y cdk4/6
EP3458091B1 (en) * 2016-05-20 2021-11-17 Eli Lilly and Company Combination therapy with notch and pd-1 or pd-l1 inhibitors
JP2019526632A (ja) * 2016-08-31 2019-09-19 イーライ リリー アンド カンパニー 固形腫瘍の治療のための投薬レジメン
EP3525796A1 (en) 2016-10-12 2019-08-21 Eli Lilly and Company Targeted treatment of mature t-cell lymphoma
LT3552017T (lt) 2016-12-09 2022-05-10 Denali Therapeutics Inc. Junginiai, naudotini kaip ripk1 inhibitoriai
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
US11066475B2 (en) 2017-11-01 2021-07-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
AU2018359907A1 (en) * 2017-11-06 2020-05-07 Fred Hutchinson Cancer Center Combination of a cell therapy and a gamma secretase inhibitor
EP3790552A4 (en) * 2018-05-06 2022-06-15 Ayala Pharmaceuticals Inc. COMBINATION COMPOSITIONS WITH BISFLUORAKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND METHODS OF USE THERE
BR112021006092A2 (pt) 2018-10-02 2021-07-20 Frequency Therapeutics, Inc. composições farmacêuticas que compreendem agentes terapêuticos óticos e métodos relacionados
MX2021012258A (es) 2019-04-08 2022-01-04 Frequency Therapeutics Inc Combinacion de chir99021 y acido valproico para tratar la perdida auditiva.
EP4463229A1 (en) 2022-01-12 2024-11-20 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9711537B (en) * 1996-12-23 1998-06-25 Athena Neurosciences Inc Eli L Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
AU4710199A (en) * 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
AU4707999A (en) 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
CN100480248C (zh) 2003-02-04 2009-04-22 弗·哈夫曼-拉罗切有限公司 用作γ-分泌酶抑制剂的丙二酰胺衍生物
BRPI0413533A (pt) 2003-09-09 2006-10-10 Hoffmann La Roche derivados de malonamida que bloqueiam a atividade de gama-secretase
SI1673347T1 (sl) 2003-10-06 2015-10-30 F. Hoffmann - La Roche Ag Substituirani derivati dibenzo-azepina in benzo-diazepina, ki so uporabni kot inhibitorji gama-sekretaze
WO2007110335A1 (en) 2006-03-27 2007-10-04 F. Hoffmann-La Roche Ag Malonamide derivatives as gamma secretase inhibitors
KR101150574B1 (ko) * 2007-02-02 2012-05-30 에프. 호프만-라 로슈 아게 6-옥소-6,7-다이하이드로-5h-다이벤조[b,d]아제핀-7-일 유도체
US20090181944A1 (en) 2008-01-11 2009-07-16 John Frederick Boylan Method for cancer therapy
WO2011060051A1 (en) * 2009-11-12 2011-05-19 University Of Massachusetts Methods for treating glioblastoma

Also Published As

Publication number Publication date
CN103732612A (zh) 2014-04-16
ES2544937T3 (es) 2015-09-07
PE20141061A1 (es) 2014-09-06
BR112014001600B1 (pt) 2022-09-13
HRP20150771T1 (hr) 2015-08-28
DOP2014000011A (es) 2014-07-31
US20130029972A1 (en) 2013-01-31
CA2841178C (en) 2016-12-20
DK2736920T3 (en) 2015-07-20
EP2736920B1 (en) 2015-07-01
ME02171B (me) 2015-10-20
EA201490161A1 (ru) 2014-04-30
PT2736920E (pt) 2015-09-16
TWI568730B (zh) 2017-02-01
US8569286B2 (en) 2013-10-29
HUE027534T2 (en) 2016-11-28
JO3148B1 (ar) 2017-09-20
JP6027110B2 (ja) 2016-11-16
BR112014001600A2 (pt) 2017-02-21
JP2014527042A (ja) 2014-10-09
CR20140036A (es) 2014-03-21
CO6862159A2 (es) 2014-02-10
KR20140026624A (ko) 2014-03-05
PH12014500215A1 (en) 2014-03-17
KR101578309B1 (ko) 2015-12-16
EP2736920A1 (en) 2014-06-04
CA2841178A1 (en) 2013-01-31
EA023044B1 (ru) 2016-04-29
AP2014007362A0 (en) 2014-01-31
TW201315732A (zh) 2013-04-16
AR087107A1 (es) 2014-02-12
SI2736920T1 (sl) 2015-08-31
AP4080A (en) 2017-03-29
AU2012287251A1 (en) 2014-01-30
WO2013016081A1 (en) 2013-01-31
PH12014500215B1 (en) 2018-09-07
MY184303A (en) 2021-03-31
NZ618891A (en) 2015-12-24
CL2014000175A1 (es) 2014-08-22
ECSP14013179A (es) 2014-03-31
GT201400012A (es) 2014-07-16
MX356536B (es) 2018-06-01
CN103732612B (zh) 2015-09-23
MA35611B1 (fr) 2014-11-01
IL229988A (en) 2017-07-31
HK1194086A1 (en) 2014-10-10
RS54135B1 (sr) 2015-12-31
CY1116645T1 (el) 2017-03-15
AU2012287251B2 (en) 2015-05-14
MX2014001084A (es) 2014-02-27

Similar Documents

Publication Publication Date Title
AP4080A (en) Notch pathway signaling inhibitor compound
IL265897A (en) Transformed imidazopyridinyl – aminopyridine compounds
ZA201400232B (en) Metalloenzyme inhibitor compounds
SMT201700596T1 (it) Composti inibitori
EP2723731A4 (en) COMPOUNDS INHIBITING METALLOENZYMES
ZA201401553B (en) Cyclopropaneamine compound
ZA201408141B (en) Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
ZA201306580B (en) Cyclopropylamines as lsd1 inhibitors
HUE037899T2 (hu) Metalloenzim inhibitor vegyületek
GB201106817D0 (en) New compound
EP2708540A4 (en) PYRIMIDO-DIAZEPINONE COMPOUND
EP2751117A4 (en) METALLOENZYMHEMMERVERBINDUNGEN
GB201211019D0 (en) Inhibitor compounds
GB201104669D0 (en) Compound
GB201108188D0 (en) Corrosion inhibitor
GB201120474D0 (en) Inhibitors
GB201104399D0 (en) Novel inhibitors
GB201004308D0 (en) New inhibitor compounds
GB201100461D0 (en) Quenching compound
GB201118102D0 (en) Compound
GB201121538D0 (en) Compound
GB201114957D0 (en) Papercut